NewcelXNCEL -0.52%33 Gross Margin % is 0.00% as of Dec. 2025. GuruFocus rates NCEL with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 730 Biotechnology companies, NewcelX ranks worse than 136986.16% on this metric.
The historical rank and industry rank for NewcelX's Gross Margin % or its related term are showing as below:
During the past 13 years, the highestGross Margin % of NewcelX was 92.89%. The lowest was 92.10%. And the median was 92.50%.
NCEL's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91 * Ranked among companies with meaningful Gross Margin % only.
NewcelX had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for NewcelX was 0.00% per year.
NewcelX (NAS:NCEL) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
NewcelX had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
NewcelX Gross Margin % Related Terms
NewcelX Gross Margin % Historical Data
* Premium members only.
The historical data trend for NewcelX's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NCEL vs LPCN, PTN, ALLR: Gross Margin % Comparison
For the Biotechnology subindustry, NewcelX's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewcelX Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NewcelX's Gross Margin % distribution charts can be found below:
* The bar in red indicates where NewcelX's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
NewcelX (NCEL) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on NewcelX and its competitors. Over the past decade, NewcelX's Gross Margin % has ranged from 92.10 to 92.89. According to the industry distribution chart, NewcelX ranks #999999 out of 730 companies in the Biotechnology industry.
Is NewcelX's Gross Margin % too high?
NewcelX's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 92.10 to a high of 92.89. Based on the distribution chart, NewcelX ranks #999999 out of 730 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NewcelX has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NewcelX's Gross Margin % compare to LPCN and PTN?
According to the Biotechnology industry distribution chart, NewcelX ranks #999999 out of 730 companies for Gross Margin %. This places NewcelX in the lower half of its industry. The industry median Gross Margin % is 60.91. Historically, NewcelX's own Gross Margin % has ranged from 92.10 to 92.89 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on NewcelX and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewcelX's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewcelX stock overvalued right now?
NewcelX (NCEL) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. NewcelX's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For NewcelX (NCEL), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
33GF Score
Get the complete analysis for NCEL
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NCEL has been successfully added to your 
